×
Ocular Therapeutix Receivables 2013-2024 | OCUL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Ocular Therapeutix receivables from 2013 to 2024. Receivables can be defined as the total amount of collectibles for a company
View More
Ocular Therapeutix Receivables 2013-2024 | OCUL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Ocular Therapeutix receivables from 2013 to 2024. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$87.5B
Takeda Pharmaceutical (TAK)
$47.5B
Merck (MKGAF)
$24.4B
Astellas Pharma (ALPMY)
$22B
Sandoz Group AG (SDZNY)
$17.6B
Summit Therapeutics (SMMT)
$16.8B
United Therapeutics (UTHR)
$15.6B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$12.2B
Catalent (CTLT)
$10.9B
Revolution Medicines (RVMD)
$7.7B
Orion OYJ (ORINY)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.2B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.3B
Crinetics Pharmaceuticals (CRNX)
$4.3B
Corcept Therapeutics (CORT)
$4.3B
Dyne Therapeutics (DYN)
$3.7B
PTC Therapeutics (PTCT)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Soleno Therapeutics (SLNO)
$2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.7B
Xencor (XNCR)
$1.7B
Harrow (HROW)
$1.6B
Cassava Sciences (SAVA)
$1.5B